Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
Vera Therapeutics (Nasdaq: VERA) announced that its management team will present at the TD Cowen Immunology & Inflammation Summit, held virtually on November 12-13, 2025. The company presentation is scheduled for Thursday, November 13, 2025 at 1:30pm ET.
Management will also hold one-on-one investor meetings. A live webcast is available at the provided link and a replay will be accessible for 90 days via the company’s Investor Calendar.
Vera Therapeutics (Nasdaq: VERA) ha annunciato che il suo team dirigenziale parteciperà all'TD Cowen Immunology & Inflammation Summit, che si terrà virtualmente il 12-13 novembre 2025. La presentazione aziendale è prevista per giovedì 13 novembre 2025 alle 13:30 ET.
Il management terrà anche incontri individuali con gli investitori. È disponibile una webcast in diretta al link fornito e una replica sarà accessibile per 90 giorni tramite il Calendario Investitori dell'azienda.
Vera Therapeutics (Nasdaq: VERA) anunció que su equipo directivo participará en la Cumbre TD Cowen Immunology & Inflammation Summit, que se llevará a cabo virtualmente los días 12-13 de noviembre de 2025. La presentación de la empresa está programada para el jueves 13 de noviembre de 2025 a las 1:30 p.m. ET.
El equipo directivo también mantendrá reuniones individuales con inversionistas. Se ofrece una transmisión en vivo a través del enlace proporcionado y una reproducción estará disponible por 90 días a través del Calendario de Inversores de la empresa.
Vera Therapeutics (Nasdaq: VERA)은 경영진이 TD Cowen Immunology & Inflammation Summit에 참여할 것이라고 발표했습니다. 이 서밋은 2025년 11월 12-13일에 가상으로 개최됩니다. 회사 발표는 2025년 11월 13일 목요일 오후 1:30 ET로 예정되어 있습니다.
경영진은 또한 투자자와의 1대1 미팅을 가질 예정입니다. 링크에서 제공된 라이브 webcast를 이용할 수 있으며 90일 동안 회사의 Investment Calendar를 통해 재생이 가능합니다.
Vera Therapeutics (Nasdaq: VERA) a annoncé que son équipe de direction participera au TD Cowen Immunology & Inflammation Summit, qui se tiendra virtuellement les 12 et 13 novembre 2025. La présentation de l'entreprise est prévue pour le jeudi 13 novembre 2025 à 13h30 ET.
La direction tiendra également des réunions individuelles avec les investisseurs. Une webdiffusion en direct est disponible via le lien fourni et une rediffusion sera accessible pendant 90 jours via le Calendrier des Investisseurs de l'entreprise.
Vera Therapeutics (Nasdaq: VERA) kündigte an, dass ihr Management-Team am TD Cowen Immunology & Inflammation Summit teilnehmen wird, der virtuell am 12.–13. November 2025 stattfindet. Die Unternehmenspräsentation ist für Donnerstag, den 13. November 2025 um 13:30 Uhr ET vorgesehen.
Das Management wird auch Einzelgespräche mit Investoren führen. Ein Live-Webcast ist über den angegebenen Link verfügbar und eine Aufnahme wird für 90 Tage über den Investor Calendar des Unternehmens zugänglich sein.
Vera Therapeutics (Nasdaq: VERA) أعلنت أن فريق إدارتها سيقدم في TD Cowen Immunology & Inflammation Summit، الذي سيعقد افترادياً في 12-13 نوفمبر 2025. العرض الرسمي للشركة مقرر ليكون يوم الخميس 13 نوفمبر 2025 الساعة 1:30 مساءً بتوقيت شرق الولايات المتحدة.
كما سيجري المديرون اجتماعات فردية مع المستثمرين. تتوفر بث مباشر live webcast من الرابط المقدم وسيكون بالإمكان الوصول إلى إعادة العرض لمدة 90 يوماً عبر تقويم المستثمرين الخاص بالشركة.
- None.
- None.
BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from November 12-13, 2025. The management team will also participate in one-on-one investor meetings.
Presentation Details:
Date: Thursday, November 13, 2025
Time: 1:30pm ET
Webcast: https://wsw.com/webcast/cowen185/vera/2021228
A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell–mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
FAQ
When will Vera Therapeutics (VERA) present at the TD Cowen Immunology & Inflammation Summit?
How can investors watch the Vera Therapeutics (VERA) presentation on November 13, 2025?
Will Vera Therapeutics (VERA) meet with investors during the TD Cowen Summit?
How long will the Vera Therapeutics (VERA) webcast replay be available?
What topics will Vera Therapeutics (VERA) cover at the TD Cowen Immunology & Inflammation Summit?
Where can I find the Vera Therapeutics (VERA) presentation replay after the summit?
